NYSE: GLASGlass House Brands Inc Stock
$9.36-0.33 (-3.41%)
Updated Aug 18, 2026
GLAS Price
$9.36
Fair Value Price
N/A
Market Cap
$777.36M
52 Week Low
$9.12
52 Week High
$12.70
P/E
-12.32x
P/B
10.7x
P/S
7x
PEG
N/A
Dividend Yield
N/A
Revenue
$164.83M
Earnings
-$52.21M
Gross Margin
30.8%
Operating Margin
-22.61%
Profit Margin
-31.7%
Debt to Equity
2.04
Operating Cash Flow
-$20M
Beta
1.49
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GLAS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
GLAS
Ranked#48 of 54
Ranked#48 of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $63.43 | A | |
| $39.43 | A | |
| $6.93 | A |
Be the first to know about important GLAS news, forecast changes, insider trades & much more!
GLAS News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GLAS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GLAS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GLAS is poor value based on its book value relative to its share price (10.7x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.64x)
P/B vs Industry Valuation
GLAS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GLAS due diligence checks available for Premium users.
Valuation
GLAS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.32x
Industry
3.3x
Market
15.03x
GLAS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.7x
Industry
1.64x
GLAS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GLAS's financial health
Profit margin
Revenue
$47.0M
Net Income
-$6.8M
Profit Margin
-14.5%
GLAS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GLAS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$313.4M
Liabilities
$148.2M
Debt to equity
2.04
GLAS's short-term assets ($71.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLAS's long-term liabilities ($94.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLAS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$179.0k
Investing
-$8.1M
Financing
$2.1M
GLAS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GLAS vs Pharmaceutical Stocks
Glass House Brands Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.